Trial | NCT00093951  Report issue

Title

SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's Disease

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    sgs-742 ...

  • Study Participants

    280
The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
SGS742 is a GABA(B) receptor antagonist. It is an orally active drug and possesses neurochemical and psychopharmacologic features that suggest it could improve memory and cognition in humans. The primary objective of the SGS742 clinical trial will be to determine the effect of SGS742 on memory and cognition in individuals diagnosed with mild to moderate Alzheimer's disease. The duration of the study is 3 months with 5 clinic visits.
Study Started
Apr 30
2004
Primary Completion
Sep 30
2007
Study Completion
Sep 30
2007
Last Update
Dec 11
2009
Estimate

Drug SGS742

Criteria 

Inclusion Criteria:

55 to 90 years of age
Diagnosed with mild to moderate Alzheimer's disease
Willing caregiver
In general good health

Exclusion Criteria:

Call 1-877-MY-MEMORY and ask to be referred to a study center located near you for entry criteria information.

Prohibited Meds:

Alzheimer's medications (Aricept, Exelon, Remydl, Nemenda)
No Results Posted